<DOC>
	<DOCNO>NCT01517412</DOCNO>
	<brief_summary>Primary Objective : - To compare two treatment regimen term change glycosylated hemoglobin ( HbA1c ) baseline endpoint ( Week 24 ) Secondary Objective : - To assess effect 2 lixisenatide regimen : - The percentage participant reach target HbA1c &lt; 7 % ≤ 6.5 % Week 24 - Fasting Plasma Glucose ( FPG ) - 7-point Self-Monitored Plasma Glucose ( SMPG ) profile - Body weight - To assess safety tolerability 2 lixisenatide regimen</brief_summary>
	<brief_title>Comparison Lixisenatide Injected Prior Main Meal Day Versus Prior Breakfast Type 2 Diabetic Patients Metformin</brief_title>
	<detailed_description>The maximum study duration 28 week per participant , include 24-week randomized treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Participants type 2 diabetes mellitus , diagnose least 1 year screen visit Metformin treatment stable dose least 1.5 g/day least 3 month prior screen visit . Exclusion criterion : Screening HbA1c &lt; 7.0 % &gt; 10.0 % Fasting plasma glucose screen &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) Treatment glucoselowering agent ( ) metformin period 3 month prior screen , previous use insulin Participants usually eat breakfast Type 1 diabetes mellitus Body Mass Index ( BMI ) ≤ 20 kg/m^2 &gt; 40 kg/m^2 Pregnancy lactation , woman childbearing potential effective contraceptive method Amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) screen Alanine aminotransferase ( ALT ) &gt; 3 ULN screen Calcitonin ≧ 20 pg/ml ( 5.9 pmol/L ) screen History unexplained pancreatitis , chronic pancreatitis , pancreatectomy . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( e.g . multiple endocrine neoplasia syndrome ) Any contraindication relate metformin Any previous treatment lixisenatide The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>